Document:

Exhibit 10.17

 Exhibit 10.17 
 EMPLOYMENT AGREEMENT 
 THIS EMPLOYMENT AGREEMENT (the
“Employment Agreement”) is entered, effective November 10, 2011 (the “Effective Date”) by and between Catalyst Health Solutions, Inc. (the “Company”) and David T. Blair (the
“Executive”). 
 1. Employment Term; Position; Duties. 

(a) Employment Term. Executive shall be employed by the Company under the terms of this Employment Agreement for a period
commencing on November 10, 2011 and ending on February 28, 2015 (the “Employment Term”). Notwithstanding the foregoing, Executive’s employment with the Company may be terminated pursuant to Section 4, on the
terms and subject to the conditions set forth in this Employment Agreement. On the date Executive’s employment with the Company ends, Executive shall cease to hold any position (whether as an officer, manager, employee, trustee, fiduciary,
member of any board or otherwise) with the Company or any of its subsidiaries or affiliates, unless Executive and the Company shall specifically agree otherwise in writing. 
 (b) Position; Duties. During the Employment Term, Executive shall serve as the Chairman of the Board of Directors of the Company (the “Board”), effective January 1, 2012, and
as the Company’s Chief Executive Officer. Executive shall principally perform his duties to the Company and its’ affiliates from the Company’s offices in Rockville, Maryland, subject to normal and customary travel requirements in the
conduct of the Company’s business. Executive shall report to the Board and shall have such duties which shall be those normally performed by a Chairman and Chief Executive Officer. During the Employment Term, Executive will devote
Executive’s full business time and best efforts to the performance of Executive’s duties hereunder and will not engage in any other business, profession, or occupation for compensation or otherwise which would conflict with the rendition
of such services either directly or indirectly, without the prior written consent of the Board; provided, that, Executive shall be permitted to serve on the board of directors of one other public company so long as such service does not materially
interfere with Executive’s duties hereunder or violate any covenant contained in the Confidentiality Addendum (as defined below). 
 2.
Compensation. 
 (a) Base Salary. During the Employment Term, Executive’s annual base salary will be $795,000
(the “Base Salary”), which shall be paid in accordance with the Company’s usual payment practices. Base Salary shall be reviewed annually and any changes to Base Salary during the term of this Employment Agreement shall be as
authorized by the Compensation Committee of the Board (the “Compensation Committee”). 
 (b) Incentive
Bonus. During the Employment Term, Executive shall be eligible to participate in an annual bonus program adopted by the Compensation Committee, which will provide Executive with the opportunity to earn a cash bonus based on performance (the
“Incentive Bonus”). The opportunity range for the Incentive Bonus will be 0% to 200% of Base Salary. 

  
 1 

 (c) Equity Compensation. During the Employment Term, Executive shall be eligible to
participate in a Long-Term Incentive Program that will be adopted by the Company (the “LTIP”). The LTIP will consist of an annual equity award that may include time-based restricted Common Stock (“Restricted
Stock”), performance-based Restricted Stock, stock options or other equity awards. The amount of equity awards granted to Executive in any one year shall be determined by the Compensation Committee and shall be subject to such other terms
and conditions as may be determined by the Compensation Committee. 
 (d) Target Compensation.
Executive’s total annual compensation (the sum of Base Salary, Incentive Bonus and equity compensation) is initially targeted to range between the 25th and 50th percentile of the Company’s peer group, as determined annually by the Compensation Committee. 

(e) Employee Benefits. During the Employment Term, Executive shall be entitled to participate in the employee benefit plans of the
Company maintained generally for employees (including, e.g., without limitation, standard medical and dental benefits, and savings plan), as well as those maintained for other senior executives of the Company, except for equity compensation and
severance which are covered in this Employment Agreement. In addition, during the Employment Term Executive shall be eligible for (i) three weeks of paid vacation per year; and (ii) term life insurance as currently in effect and to be
maintained in an amount equal to at least three times Executive’s Base Salary. 
 (f) Business Expenses. During the
Employment Term, reasonable business expenses incurred by Executive in the performance of Executive’s duties hereunder shall be reimbursed by the Company in accordance with Company policies. 

3. Special Equity Award. See description on Appendix C. 
 4. Termination. 
 (a) General. The Employment Term and
Executive’s employment hereunder may be terminated by either party at any time and for any reason in accordance with the provisions of this Section 4. Notwithstanding any other provision of this Employment Agreement, the provisions of this
Section 4 shall exclusively govern Executive’s rights upon termination of employment with the Company and its affiliates. Any purported termination of employment by the Company or by Executive (other than due to Executive’s death)
shall be communicated by written Notice of Termination to the other party hereto in accordance with Section 6(j) hereof. For purposes of this Employment Agreement, a “Notice of Termination” shall mean a notice which shall indicate the
specific termination provision in this Employment Agreement relied upon and shall set forth in reasonable detail the facts and circumstances claimed to provide a basis for termination of employment under the provision so indicated. 

(b) By the Company for Cause, by Executive without Good Reason, or Due to Death or Permanent Disability. The Employment Term and
Executive’s employment hereunder (i) may be terminated immediately by the Company for Cause (as defined below) at any time, (ii) may be terminated by Executive without Good Reason upon not less than 90 days advance written notice to
the Company, (iii) will terminate upon Executive’s death, and (iv) may be terminated by the Company due 

  
 2 

 
to Executive’s Permanent Disability. If Executive’s employment is terminated pursuant to this Section 4(b), then Executive (or Executive’s estate in the event of death) shall
only be entitled to receive the Accrued Obligations; provided, that, in the event Executive’s employment is terminated pursuant Section 4(b)(iii) or (iv), then Executive (or Executive’s estate in the event of death) shall also be
entitled to the benefits set forth in Sections 4(c)(ii) through 4(c)(v), subject to Executive’s compliance with the last paragraph of Section 4(c) in the event Executive’s termination is due to Executive’s Permanent Disability.
If Executive provides a Notice of Termination without Good Reason, then the Company may accelerate the date of termination and such termination shall still be considered a termination by Executive without Good Reason. 

(c) By the Company Without Cause or by Executive with Good Reason. The Employment Term and Executive’s employment hereunder
(i) may be terminated by the Company at any time without Cause, and (ii) may be terminated by Executive for Good Reason. If Executive’s employment is terminated pursuant to this Section 4(c), then Executive shall be entitled to
receive: 
 (i) Two times the sum of (A) Executive’s Base Salary, and (B) the average of Executive’s cash
Incentive Bonus paid (or payable) to Executive for the three completed calendar years immediately preceding the calendar year in which the termination date occurs, which amount shall be paid in the form of salary continuation over the twenty four
(24) month period following the termination date in accordance with the Company’s normal payroll practices as in effect on the date of termination of Executive’s employment, except that any payments that would otherwise have been made
before the first normal payroll payment date falling on or after the sixtieth (60th) day after the date of termination of Executive’s employment (the “First Payment Date”) shall be made on the First Payment Date;

 (ii) Continuation of healthcare benefits for Executive and his eligible dependents at the Company’s expense for the
premium payments for a period of twenty four (24) months following the termination date; 
 (iii) All equity awards
(including portions thereof) held by Executive that primarily vest based on the passage of time and do not vest based on the achievement of performance goals, that would have vested in the twelve (12) month period following Executive’s
date of termination had Executive remained employed by the Company during such twelve (12) month period shall be immediately vested on the date the Release becomes effective and shall be forfeited if the Release does not become effective within
the time period set forth below; 
 (iv) All unvested equity awards (including portions thereof) held by Executive that vest
based on the achievement of performance goals shall be forfeited by Executive; provided, that the Compensation Committee may, in its discretion, accelerate the vesting of all or a portion of unvested performance based equity awards if it determines
that the performance goals related to the applicable award have been or would be achieved; 

  
 3 

 (v) Any Incentive Bonus earned for a performance period that has ended prior to the date of
termination that remains unpaid as of the date of termination; and 
 (vi) Any Accrued Obligations. 

Notwithstanding any provision to the contrary in this Employment Agreement, Executive shall not be eligible to receive the payments and benefits set
forth in this Section 4(c) or set forth in Section 4(d) unless Executive continues to comply with his obligations under the Confidentiality Addendum and (x) on or prior to the 50th day following the date of his termination, Executive
executes and delivers to the Company a waiver and release of claims agreement, in the form attached hereto as Appendix B (the “Release”), which Release may be amended by the Company to reflect changes in applicable laws and
regulations, and (y) such Release shall not have been revoked by Executive on or prior to the 60th day following the date of his termination. The payments under Sections 4(c) and 4(d) are intended to constitute separate payments for purposes of
Section 1.409A-2(b)(2) of the Treasury Regulations. 
 (d) Termination Within 12 Months After Change
in Control. Subject to the last paragraph of Section 4(c), in the event that Executive’s employment is terminated within twelve months after a Change in Control (to the extent the Change in Control constitutes a “change in control
event” under Section 409A) by the Company without Cause or by Executive for Good Reason, Executive shall be entitled to (i) the same rights, payments and benefits as provided in Section 4(c), except the amount provided in
Section 4(c)(i) shall be paid in a lump sum on the First Payment Date (but in no event later than
March 15th of the calendar year following the
calendar year in which the termination occurs); and (ii) full vesting of time-based restricted stock and full vesting at target level of any then outstanding equity award that prior to the date of the Change in Control primarily vested based on
the achievement of performance goals, which vesting shall occur on the date the Release becomes effective. 
 (e)
Disputes. If any contest or dispute shall arise under this Employment Agreement involving termination of Executive’s employment with the Company within twelve (12) months after a Change in Control, the Company shall reimburse
Executive for all reasonable legal fees and related expenses, if any, incurred by Executive in connection with such contest or dispute if a court of competent jurisdiction or an arbitration panel substantially upholds Executive’s position,
provided, that the Company shall make any such reimbursement to Executive as soon as practicable after such reimbursement becomes due, but in no event later than December 31st of the year following the year in which the applicable fees and
related expenses were incurred. The amount of expenses reimbursed in one year shall not affect the amount eligible for reimbursement in any subsequent year. 
 (f) Section 409A. Notwithstanding anything to the contrary in this Section 4, Executive shall not be entitled to any severance payments or benefits pursuant to this Section 4 that
provide for deferral of compensation covered by Section 409A of the Internal Revenue Code of 1986, as amended (“Section 409A”) unless Executive’s termination of employment constitutes a “separation from service”
within the meaning of Treasury Regulation Section 1.409A-1(h). If, at the time Executive experiences a “separation from service,” the Company determines that Executive is a “specified employee,” as defined in
Section 409A (and the regulations promulgated thereunder), then notwithstanding anything to the contrary in this Employment Agreement, any and all amounts payable under this Section 4 that would constitute deferred compensation subject to
Section 409A, as determined by the Company in its sole discretion, and that would (but for this sentence) be payable 

  
 4 

 
within the six (6) month period following such separation from service, shall instead be paid on the thirtieth day following the expiration of the six (6) month period following the
separation from service, in the form of a lump sum. Each payment under this Employment Agreement shall be considered a separate and distinct payment for purposes of Section 409A. Notwithstanding the prior sentence or anything to the contrary in
this Employment Agreement, the Company may accelerate the timing of any payment or benefit payable to Executive under this Employment Agreement without Executive’s consent to the extent such acceleration does not cause adverse tax consequences
to Executive under Section 409A. 
 5. Confidentiality. Executive acknowledges and agrees that the provisions of the Confidentiality
and Non-Competition Addendum previously executed by Executive (the “Confidentiality Addendum”) is made a part hereof and will continue to apply during the Employment Term and thereafter in accordance with its terms. Executive agrees
that in consideration for the additional benefits under this Agreement and to further protect the Company’s confidential information and intellectual property, the restrictions set forth in Section IV of the Confidentiality Addendum shall be
extended and shall remain in effect for twenty-four (24) months following Executive’s termination of employment. 
 6.
Miscellaneous. 
 (a) Governing Law. This Employment Agreement shall be governed by and construed in accordance
with the laws of the State of Maryland, without regard to conflicts of laws principles thereof. 
 (b) Definitions.
Capitalized terms not defined herein shall have the meaning set forth in Appendix A. 
 (c) Claw-Back. All
compensation received by Executive shall be subject to the provisions of any claw-back policy implemented by the Company to comply with applicable law, regulation or stock exchange rule, including, without limitation, any claw-back policy adopted to
comply with the requirements of the Dodd-Frank Wall Street Reform and Consumer Protection Act and any rules or regulations promulgated thereunder. 
 (d) 280G. Notwithstanding anything contained in this Employment Agreement to the contrary, any payment or benefit received or to be received by Executive in connection with a “change in
control event” that would constitute a “parachute payment” (each within the meaning of Section 280G of the Internal Revenue Code of 1986, as amended (the “Code”)), whether payable pursuant to the terms of this
Employment Agreement or any other plan, arrangement or agreement with the Company or any affiliate (collectively, the “Total Payments”), shall be reduced to the least extent necessary so that no portion of the Total Payments shall
be subject to the excise tax imposed by Section 4999 of the Code, but only if, by reason of such reduction, the Net After-Tax Benefit received by Executive as a result of such reduction will exceed the Net After-Tax Benefit that would have been
received by Executive if no such reduction was made. If excise taxes may apply to the Total Payments, the foregoing determination will be made by a nationally recognized accounting firm (the “Accounting Firm”) selected by the
Company and reasonably acceptable to Executive. If the Accounting Firm determines that a reduction in payments is required by this Section, cash benefits, including the severance provided in Section 4, shall first be reduced, followed by a
reduction of non-

  
 5 

 
cash benefits, including option vesting acceleration, in each case, (i) only to the least extent necessary so that no portion thereof shall be subject to the excise tax imposed by
Section 4999 of the Code, and (ii) in a manner that results in the best economic benefit to Executive, and the Company shall pay or provide such reduced amounts to Executive in accordance with the provisions above. If applicable, Executive
and the Company will each provide the Accounting Firm access to and copies of any books, records and documents in their respective possession, reasonably requested by the Accounting Firm, and otherwise cooperate with the Accounting Firm in
connection with the preparation and issuance of the determinations and calculations contemplated by this Section. The fees and expenses of the Accounting Firm for its services in connection with the determinations and calculations contemplated by
this Section will be borne by the Company. 
 (e) Entire Agreement/Amendments. This Employment Agreement (together with
its appendices and the Confidentiality Addendum) contains the entire understanding of the parties with respect to the employment of Executive by the Company and supersedes in its entirety the employment agreements between the Company and Executive
originally effective January 1, 2000, July 1, 2005 and February 28, 2008. There are no restrictions, agreements, promises, warranties, covenants, or undertakings between the parties with respect to the subject matter herein other
than those expressly set forth herein. This Employment Agreement may not be altered, modified, or amended except by written instrument signed by the parties hereto. 
 (f) No Waiver. The failure of a party to insist upon strict adherence to any term of this Employment Agreement on any occasion shall not be considered a waiver of such party’s rights or
deprive such party of the right thereafter to insist upon strict adherence to that term or any other term of this Employment Agreement. 
 (g) Severability. In the event that any one or more of the provisions of this Employment Agreement shall be or become invalid, illegal, or unenforceable in any respect, the validity, legality, and
enforceability of the remaining provisions of this Employment Agreement shall not be affected thereby. 
 (h) Assignment.
This Employment Agreement shall not be assignable by Executive. This Employment Agreement may be assigned by the Company to a company which is a successor in interest to substantially all of the business operations of the Company. Such assignment
shall become effective when the Company notifies Executive of such assignment or at such later date as may be specified in such notice. Upon such assignment, the rights and obligations of the Company hereunder shall become the rights and obligations
of such successor company, provided that any assignee expressly assumes the obligations, rights, and privileges of this Employment Agreement. 
 (i) Successors; Binding Agreement. This Employment Agreement shall inure to the benefit of and be binding upon the personal or legal representatives, executors, administrators, successors, heirs,
distributees, devises, and legatees of the respective parties to this Employment Agreement. 
 (j) Notice. For the
purposes of this Employment Agreement, notices and all other communications provided for in the Employment Agreement shall be in writing and shall be deemed to have been duly given when delivered or mailed by United States registered mail, return
receipt 

  
 6 

 
requested, postage prepaid, and addressed to the respective addresses set forth below or to such other address as either party may have furnished to the other in writing in accordance herewith.
Notice of change of address shall be effective only upon receipt. 
  

			
	 If to the Company:
	  	Catalyst Health Solutions, Inc.
		  	800 King Farm Boulevard
		  	Rockville, MD 20850
		  	Attn: General Counsel
		
	 If to Executive:
	  	To the most recent address of Executive set forth in the personnel records of the Company.

 (i) Withholding Taxes. The Company may withhold from any amounts payable under this Employment
Agreement such federal, state, and local taxes as may be required to be withheld pursuant to any applicable law or regulation. 

(j) Counterparts. This Employment Agreement may be signed in counterparts, each of which shall be an original, with the same
effect as if the signatures thereto and hereto were upon the same instrument. 
 [The remainder of this page intentionally
left blank. Signature page follows.] 

  
 7 

 IN WITNESS WHEREOF, the parties hereto have duly executed this Employment Agreement
as of the day and year first above written. 
  

							
	Catalyst Health Solutions, Inc.	 		 	Executive
				
	BY:	 	 /s/ Dale B. Wolf
	 		 	 /s/ David T. Blair

				
	TITLE:	 	Compensation Committee Chairman	 		 	

  
 8 

 APPENDIX A 

TO THE EMPLOYMENT AGREEMENT DATED NOVEMBER 10, 2011 
 BETWEEN CATALYST HEALTH SOLUTIONS, INC. AND DAVID T. BLAIR 
 Definitions

 Accrued Obligations. For purposes of this Employment Agreement, “Accrued Obligations” shall mean (i) Base
Salary earned through Executive’s date of termination but not paid to Executive; (ii) reimbursement for any unreimbursed business expenses properly incurred by Executive in accordance with Company policy prior to the date of
Executive’s termination; and (iii) such employee benefits, if any, as to which Executive may be entitled under the terms of the employee benefit plans of the Company. 
 Cause. For purposes of this Employment Agreement, “Cause” shall mean Executive’s: (i) failure to comply with any law or regulation arising from conduct not undertaken in
good faith; (ii) commission of an act of fraud upon, or act evidencing dishonesty to, the Company or any of its affiliates; (iii) misappropriation of any funds, property, or rights of the Company or any of its affiliates; (iv) willful
breach or habitual neglect of Executive’s job duties or Executive’s failure or refusal to comply with explicit directives of the Board; (v) conviction of a felony; (vi) use or possession of illegal drugs at work or
Executive’s working under the influence of drugs at work; or (vii) Executive’s breach of the provisions of any non-competition or confidentiality agreements with, or written policies of, the Company or its affiliates to which
Executive is bound or subject. 
 Change in Control. For purposes of this Employment Agreement, “Change in Control”
means the occurrence of any one of the following events: 
 (i) individuals who, on November 10, 2011
constitute the Board (the “Incumbent Directors”) cease for any reason within any twenty-four (24) month period to constitute at least a majority of the Board (or the board of directors of any successor to the Company), provided
that any person becoming a director subsequent to such date whose election or nomination for election was approved by a vote of at least two-thirds of the Incumbent Directors then on the Board (either by a specific vote or by approval of the proxy
statement of the Company in which such person is named as a nominee for director, without written objection to such nomination) shall be an Incumbent Director; provided, however, that no individual initially elected or nominated as a
director of the Company as a result of an actual or threatened election contest with respect to directors or as a result of any other actual or threatened solicitation of proxies by or on behalf of any person other than the Board (including by
reason of any agreement intended to avoid or settle such election contest or solicitation of proxies) shall be deemed to be an Incumbent Director until twenty-four (24) months after such election; 

(ii) any “person” (as such term is defined in Section 3(a)(9) of the Securities Exchange Act of 1934, as
amended (the “Exchange Act”) and as used in Sections 13(d)(3) and 14(d)(2) of the Exchange Act) is or becomes a “beneficial owner” (as defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of
securities of the Company representing 35% or more of the combined voting power of the Company’s then outstanding securities eligible to vote for the election of the Board (the “Company Voting Securities”); provided,
however, that the event described in this paragraph (ii) shall not be deemed to be a Change in Control by virtue of any of the following acquisitions: (A) by the Company or any Subsidiary, (B) by any employee benefit plan
(or related trust) sponsored or maintained by the Company or any Subsidiary, (C) by 

  
 9 

 
any underwriter temporarily holding securities pursuant to an offering of such securities, (D) pursuant to a Non-Qualifying Transaction, as defined in paragraph (iii), or (E) by any
person of Company Voting Securities from the Company, if a majority of the Incumbent Board approves in advance the acquisition of beneficial ownership of 35% or more of Company Voting Securities by such person; 

(iii) the consummation of a merger, consolidation, statutory share exchange or similar form of corporate transaction
involving the Company or any of its Subsidiaries that requires the approval of the Company’s stockholders, whether for such transaction or the issuance of securities in the transaction (a “Business Combination”), unless
immediately following such Business Combination: (A) more than 50% of the total voting power of (x) the corporation resulting from such Business Combination (the “Surviving Corporation”), or (y) if applicable, the
ultimate parent corporation that directly or indirectly has beneficial ownership of at least 90% of the voting securities eligible to elect directors of the Surviving Corporation (the “Parent Corporation”), is represented by Company
Voting Securities that were outstanding immediately prior to such Business Combination (or, if applicable, is represented by shares into which such Company Voting Securities were converted pursuant to such Business Combination), and such voting
power among the holders thereof is in substantially the same proportion as the voting power of such Company Voting Securities among the holders thereof immediately prior to the Business Combination, (B) no person (other than any employee
benefit plan (or related trust) sponsored or maintained by the Surviving Corporation or the Parent Corporation), is or becomes the beneficial owner, directly or indirectly, of 35% or more of the total voting power of the outstanding voting
securities eligible to elect directors of the Parent Corporation (or, if there is no Parent Corporation, the Surviving Corporation) and (C) at least a majority of the members of the board of directors of the Parent Corporation (or, if there is
no Parent Corporation, the Surviving Corporation) following the consummation of the Business Combination were Incumbent Directors at the time of the Board’s approval of the execution of the initial agreement providing for such Business
Combination (any Business Combination which satisfies all of the criteria specified in (A), (B) and (C) above shall be deemed to be a “Non-Qualifying Transaction”); or 

(iv) the consummation of a sale of all or substantially all of the Company’s assets. 

Notwithstanding the foregoing, a Change in Control of the Company shall not be deemed to occur solely because any person acquires beneficial ownership of
more than 35% of the Company Voting Securities as a result of the acquisition of Company Voting Securities by the Company which reduces the number of Company Voting Securities outstanding; provided, that if after such acquisition by
the Company such person becomes the beneficial owner of additional Company Voting Securities that increases the percentage of outstanding Company Voting Securities beneficially owned by such person to more than 50% of the Company Voting Securities,
a Change in Control of the Company shall then occur. 

  
 10 

 Good Reason. “Good Reason” means (i) the assignment to Executive of any
duties inconsistent in any material respect with Executive’s position (including status, offices, titles, and reporting relationships), authority, duties, or responsibilities as of the Effective Date; and (ii) the Company’s failure to
honor all of the terms of this Employment Agreement, excluding for such purpose any isolated, insubstantial, and inadvertent action not taken in bad-faith and which is remedied by the Company promptly after receipt of written notice thereof from
Executive. In order for a termination of employment by Executive to be considered to have been made for Good Reason, Executive must provide Notice of Termination in writing to the Board within four calendar months after the occurrence of the event
constituting Good Reason and Good Reason shall in no event exist if the Company substantially cures the action set forth as grounds for Good Reason within thirty (30) days following the date of such notice. During the twelve month period
following a Change in Control, “Good Reason” shall also include (i) any requirement of the Company that Executive (a) be based anywhere more than fifty (50) miles from Executive’s primary office location and more than
fifty (50) miles from Executive’s principal residence at the time of the Change in Control or (b) travel on Company business to an extent substantially greater than the travel obligations of Executive immediately prior to such Change
in Control; and (ii) the Company’s failure to continue to provide Executive with benefits in the aggregate substantially equivalent to the benefits Executive was entitled to under the employee benefit plans of the Company in which
Executive was participating immediately prior to such Change in Control, at a substantially equivalent cost. 
 Net After-Tax Benefit.
“Net After-Tax Benefit” means (i) the Total Payments that Executive becomes entitled to receive from the Company or its affiliates which would constitute “parachute payments” within the meaning of Code
Section 280G, less (ii) the amount of all federal, state and local income and employment taxes payable with respect to the Total Payments, calculated at the maximum applicable marginal income tax rate, less (iii) the amount of excise
taxes imposed with respect to the Total Payments under Section 4999 of the Code. 
 Permanent Disability. Whether a
“Permanent Disability” exists shall be determined based upon the ability of Executive to perform the functions of Chief Executive Officer. The determination that Executive is permanently disabled for purposes of any Company paid
disability policy with respect to Executive shall be proof that Executive is permanently disabled. 

  
 11 

 APPENDIX B 

TO THE EMPLOYMENT AGREEMENT DATED NOVEMBER 10, 2011 
 BETWEEN CATALYST HEALTH SOLUTIONS, INC. AND DAVID T. BLAIR 
 Release
of Claims 
 FOR AND IN CONSIDERATION OF the benefits to be provided me in connection with my termination from
employment with the Company, as such benefits are set forth in the Employment Agreement between me and Catalyst Health Solutions, Inc. (the “Company”), dated as of November 10, 2011 (the “Employment
Agreement”), my receipt of which is conditioned on my signing this Release of Claims and to which I am not otherwise entitled, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, I, on
my own behalf and on behalf of my spouse, child or children, heirs, executors, administrators, beneficiaries, devisees, representatives, attorneys, successors, and assigns, and all others claiming through me, hereby release, forever discharge, and
covenant not to sue the Company, its subsidiaries, its other affiliates, and all of their respective past, present and future officers, directors, trustees, fiduciaries, shareholders, employees, agents, administrators, general and limited partners,
members, managers, joint venturers, representatives, successors and assigns, and all others connected with any of them (all of the foregoing, the “Released”), both individually and in their official capacities, from any and all
causes of action, rights and claims of any type or description, known or unknown, which I have had in the past, now have, or might now have, through the date of my signing of this Release of Claims, including, without limitation, any and all causes
of action, rights or claims in any way resulting from, arising out of or connected with my employment by the Company or any of its subsidiaries or other affiliates or my termination from employment with the Company or pursuant to any federal, state
or local law, regulation or other requirement (including, without limitation, Title VII of the Civil Rights Act of 1964, the Age Discrimination in Employment Act, the Americans with Disabilities Act, the Fair Labor Standards Act, and the laws
addressing fair employment practice of the state or states in which I have been employed by the Company or any of its subsidiaries or other affiliates, as each may be amended from time to time). Capitalized terms used in this Release of Claims which
are defined in the Employment Agreement are used herein with the meanings so defined. 
 In signing this Release of Claims, I
acknowledge my understanding that I may not sign this Release of Claims prior to my termination from employment with the Company, but that I may consider the terms of this Release of Claims for up to fifty (50) days from the date of my
termination from employment with the Company. I also acknowledge that I am advised by the Company and its subsidiaries and other affiliates to seek the advice of an attorney prior to signing this Release of Claims; that I have had sufficient time to
consider this Release of Claims and to consult with an attorney, had I wished to do so, or to consult with any other person of my choosing before signing; and that I am signing this Release of Claims voluntarily and with a full understanding of its
terms. I further acknowledge that, in signing this Release of Claims, I have not relied on any promises or representations, express or implied, that are not set forth expressly in the Employment Agreement. I understand that I may revoke this Release
of Claims at any time within seven (7) days of the date that I signed this Release of Claims by giving written notice to the General Counsel of the Company and that this Release of Claims will take effect only upon the expiration of such
seven-day revocation period and only if I have not timely revoked it. I also understand that, if I do revoke this Release of Claims in a timely manner, the Company (including its subsidiaries and affiliates) will be relieved of all further
obligations to me under the Employment Agreement. 

  
 12 

 The Release shall be subject to Sections 6(a), 6(g) and 6(h) of the Employment
Agreement to the same extent as such sections apply to the Employment Agreement. This Release is final and binding and may not be changed or modified except in a writing signed by me and the Company. 

Intending to be legally bound, I have signed this Release of Claims under seal as of the date written below. 

 

			
	Signature:	 	  

			
	
	Name (please print): David T. Blair

			
		
	Date Signed:	 	  

  

			
	Catalyst Health Solutions, Inc.
		
	By:	 	  

			
		
	Title:	 	  

  
 13 

 APPENDIX C 

TO THE EMPLOYMENT AGREEMENT DATED NOVEMBER 10, 2011 
 BETWEEN CATALYST HEALTH SOLUTIONS, INC. AND DAVID T. BLAIR 
 Special
Equity Award 
 No later than December 31, 2011, Executive shall be granted a one-time award of 75,000 shares of Company common
stock (the “Common Stock”), subject to vesting based upon achievement of pre-established performance criteria (the “Performance Share Award”) over a three-year performance period from January 1, 2012 through
December 31, 2014. The performance vesting criteria will be determined by the Compensation Committee and shall be based on total shareholder return, the Company’s diluted earnings per share growth and management development and succession
planning. The shares of Common Stock subject to the Performance Share Award that vest shall be subject to non-transferability restrictions until the earlier of (x) January 1, 2016, and (y) the date of a Change in Control, except with
respect to those shares that Executive chooses to sell to cover withholding taxes incurred by Executive in connection with the vesting of the Performance Share Award. The Performance Share Award shall be subject to such other terms and conditions as
may be determined by the Compensation Committee and shall be in addition to the target compensation set forth in Section 2(d). 

  
 14Exhibit 10.26

 Exhibit 10.26 
 VOLUNTARY SEPARATION AND RELEASE AGREEMENT 
 This Voluntary Separation and
Release Agreement (this “Release Agreement”) is dated as of February 22, 2012, and entered into by and between Bruce Metge, an individual (“Executive”) and Catalyst Health Solutions, Inc. (together with any
successor thereto, the “Company”). 
 WHEREAS, Executive has been employed by the Company and, by letter
dated January 19, 2012, informed the Company of his intention to resign from the Company; 
 WHEREAS,
Executive’s employment by the Company will end effective as of the end of the day on March 1, 2012 (the “Resignation Date”), and the parties desire to enter into this Release Agreement upon the terms set forth herein;

 WHEREAS, due to Executive’s exemplary service to the Company, the Company wishes to provide Executive the
benefits provided herein; and 
 WHEREAS, Executive is party to a Confidentiality and Non-Competition Addendum with the
Company (the “Addendum”). 
 NOW, THEREFORE, in consideration of the covenants undertaken and the
releases contained in this Release Agreement, and in consideration of the Company’s desire and willingness to pay severance benefits (conditioned upon the terms of this Release Agreement), to which Executive is not otherwise entitled, the
parties hereby agree as follows: 
 1. Resignation; Consultation. Executive’s employment with the Company will
terminate on the Resignation Date. Executive agrees to remain an employee of the Company through the Resignation Date and agrees to continue to perform the duties associated with his position through the Resignation Date. Effective as of the
Resignation Date, Executive hereby resigns from his employment with the Company, and further resigns from any other officer or director positions Executive holds with the Company and/or any of its affiliated entities. Notwithstanding the foregoing,
for a period of ten (10) months following the Resignation Date (the “Consulting Service Period”), Executive agrees to provide consulting services to the Company as may be reasonably requested by the Company from time to time
(the “Consulting Services”); provided, that, the Consulting Service Period shall terminate on the date Executive enters into a consulting, employment or other service relationship with an entity other than the Company. 

2. Severance. Subject to Executive’s continued compliance with the terms and conditions of this Release Agreement and the
Addendum, Executive’s non-revocation of this Release Agreement, and (only with respect to Section 2(b) below) Executive’s execution and non-revocation of the Bring Down Release, Executive shall be entitled to the following severance
benefits: 
  

	 	a.	subject to Executive continuing to provide Consulting Services, through the Consulting Service Period the Company will pay Executive a monthly consulting fee equal to
$3,000, less applicable tax withholding; 

  
 1 

	 	b.	the Company will make nine (9) monthly premium payments directly to the applicable insurance provider in order to allow Executive to continue medical benefit
coverage under COBRA for Executive, Executive’s spouse and eligible dependents until December 31, 2012. In order to allow the continuation of such medical benefits, Executive agrees to timely elect COBRA continuation coverage for himself,
his spouse and eligible dependents; and 

  

	 	c.	on the date the Bring Down Release becomes effective, Executive will vest in the remaining 2,500 shares of Company common stock subject to the restricted stock award
granted to Executive on September 10, 2008. 

 3. Confidentiality and Non-Competition Addendum. The
Company and Executive hereby agree that the Addendum shall survive execution of this Release Agreement; provided, that, Section IV of the Addendum shall only last until December 31, 2012. Executive and the Company hereby agree that they shall
continue to abide by the terms, conditions and restrictions of the Addendum in accordance with the provisions thereof. 
 4.
Unvested Restricted Stock. Except as provided in Section 2 above, all unvested shares of restricted common stock of the Company held by Executive as of the Resignation Date shall be forfeited on the Resignation Date. 

5. Release. Executive, on behalf of himself, his descendants, dependents, heirs, executors, administrators, assigns, and
successors, and each of them, hereby covenants not to sue and fully releases and discharges the Company and each of its parents, subsidiaries and affiliates, past and present, as well as each of their trustees, directors, officers, members,
managers, partners, agents, attorneys, insurers, employees, stockholders, representatives, assigns, and successors, past and present, and each of them, hereinafter together and collectively referred to as the “Releasees,” with
respect to and from any and all claims, wages, demands, rights, liens, agreements or contracts (written or oral), covenants, actions, suits, causes of action, obligations, debts, costs, expenses, attorneys’ fees, damages, judgments, orders and
liabilities of whatever kind or nature in law, equity or otherwise, whether now known or unknown, suspected or unsuspected, and whether or not concealed or hidden (each, a “Claim”), which Executive now owns or holds or Executive has
at any time heretofore owned or held or may in the future hold as against any of said Releasees arising out of or in any way connected with Executive’s service as an officer, director, employee, member or manager of any Releasee and/or
Executive’s separation from his position as an officer, director, employee, manager and/or member, as applicable, of any Releasee, resulting from any act or omission by or on the part of said Releasees, or any of them, committed or omitted on
or prior to the Resignation Date including, without limiting the generality of the foregoing, any Claim under Title VII of the Civil Rights Act of 1964, the Americans with Disabilities Act, the Family and Medical Leave Act of 1993, the Worker
Adjustment and Retraining Notification Act (or any similar state, local or foreign law), the Maryland Fair Employment Practices Act, the Maryland Wage and Hour Law, or any other federal, state or local law, regulation, or ordinance, or any Claim for
compensation or benefits, including any severance pay, bonus, sick leave, holiday pay, vacation pay, life insurance, disability insurance, health or medical insurance, retirement benefits, workers’ compensation or any other fringe benefit;
provided that such release shall not apply to any of the 

  
 2 

 
following: (a) any right to indemnification that Executive may have pursuant to the bylaws (or similar governing document) of the Company or any of its parents, subsidiaries or other
affiliates, the certificate of incorporation (or similar governing document) of the Company or any of its parents, subsidiaries or other affiliates, or pursuant to any statute, law, or common law principle; (b) any rights that Executive may
have to insurance coverage for any losses, damages, fees or other expenses under any Company (or parent, subsidiary or affiliate) directors and officers liability insurance policy; (c) any rights to continued medical or dental coverage that
Executive may have under COBRA (or similar applicable state law); (d) any rights that Executive may have under this Release Agreement; (e) any base salary amounts earned by Executive prior to the Resignation Date and not paid prior to the
Resignation Date, reimbursement for any unreimbursed business expenses properly incurred by Executive in accordance with Company policy prior to the Resignation Date and any accrued but unpaid vacation, to the extent payable pursuant to Company
policy or (f) any rights to payment of vested benefits (other than severance benefits and, for the avoidance of doubt, any right to bonus amounts) that Executive may have under any other benefit plan sponsored or maintained by the Company. In
addition, this Release Agreement does not cover any Claim that cannot be so released as a matter of applicable law. Executive acknowledges and agrees that he has received any and all leave and other benefits that he has been and is entitled to
pursuant to the Family and Medical Leave Act of 1993. 
 Executive understands that as a condition to receiving the
severance pursuant to Section 2, Executive must execute an additional release of claims on the Resignation Date in the form attached hereto as Exhibit A (the “Bring Down Release”). 

Company hereby releases Executive with respect to and from any and all claims, wages, demands, rights, liens, agreements or contracts
(written or oral), covenants, actions, suits causes of action, obligations, debts, costs, expenses, attorneys’ fees, damages, judgments, orders and liabilities of whatever kind or nature in law, equity or otherwise (each, a “Company
Claim”) which Company now owns or holds, has at any time heretofore owned or held or may in the future hold against Executive for any negligent act taken by Executive in the direct conduct of his duties as an officer, director, employee, member
or manager of the Company committed prior to the Resignation Date; provided, that such release does not apply to any of the following: (a) any crimes committed by Executive; (b) any conduct constituting gross negligence, fraud, or
misconduct (c) any conduct unknown to the Chief Executive Office of the Company on the date of this Release Agreement; or (d) any rights that the Company may have under this Release Agreement. 

6. ADEA Waiver. Executive expressly acknowledges and agrees that by entering into this Release Agreement, Executive is waiving any
and all rights or Claims that he may have arising under the Age Discrimination in Employment Act of 1967, as amended (the “ADEA”), which have arisen on or before the Resignation Date. Executive further expressly acknowledges and
agrees that: 
 a. In return for this Release Agreement and the Bring Down Release, the Executive will be
entitled to receive consideration beyond that which the Executive was already entitled to receive before entering into this Release Agreement; 

  
 3 

 b. Executive is hereby advised in writing by this Release Agreement to
consult with an attorney before signing this Release Agreement; 
 c. Executive has voluntarily chosen to enter
into this Release Agreement and has not been forced or pressured in any way to sign it; 
 d. Executive is hereby
informed that he has twenty-one (21) days within which to consider this Release Agreement; 
 e. Executive
is hereby informed that he has seven (7) days following the date he executes this Release Agreement in which to revoke this Release Agreement, and this Release Agreement will become null and void if Executive elects revocation during that time.
Any revocation must be in writing and must be delivered personally or sent by facsimile or certified or registered mail, postage prepaid, to the Company during the seven-day revocation period, as follows: 

Catalyst Health Solutions, Inc. 
 800 King Farm Boulevard 
 Rockville, MD 20850 

Attention: Benjamin R. Preston, General Counsel 
 In the event that Executive timely exercises his right of revocation under this Release Agreement or the Bring Down Release, neither the Company nor Executive will have any obligations under this Release
Agreement; and 
 f. Nothing in this Release Agreement prevents or precludes Executive from challenging or
seeking a determination in good faith of the validity of this waiver under the ADEA, nor does it impose any condition precedent, penalties or costs from doing so, unless specifically authorized by federal law. 

7. No Transferred Claims. Executive warrants and represents that the Executive has not heretofore assigned or transferred to any
person not a party to this Release Agreement any released matter or any part or portion thereof and he shall defend, indemnify and hold the Company and each of its affiliates harmless from and against any claim (including the payment of
attorneys’ fees and costs actually incurred whether or not litigation is commenced) based on or in connection with or arising out of any such assignment or transfer made, purported or claimed. 

8. Property Return. No later than the Resignation Date, Executive shall return all Company-owned property in Executive’s
possession, including but not limited to all keys to Company buildings or property, automobiles or other vehicles, all Company-owned equipment, all Company software and computers, all documents and papers (including but not limited to reports,
Rolodexes, sales data, product lists, business plans, notebook entries, and files), all Company credit cards, telephone cards, cellular telephone(s), all confidential information and all other Company property. 

  
 4 

 9. Severability. It is the desire and intent of the parties hereto that the
provisions of this Release Agreement be enforced to the fullest extent permissible under the laws and public policies applied in each jurisdiction in which enforcement is sought. Accordingly, if any particular provision of this Release Agreement
shall be adjudicated by a court of competent jurisdiction to be invalid, prohibited or unenforceable under any present or future law, such provision, as to such jurisdiction, shall be ineffective, without invalidating the remaining provisions of
this Release Agreement or affecting the validity or enforceability of such provision in any other jurisdiction; furthermore, in lieu of such invalid or unenforceable provision there will be added automatically as a part of this Release Agreement, a
legal, valid and enforceable provision as similar in terms to such invalid or unenforceable provision as may be possible. Notwithstanding the foregoing, if such provision could be more narrowly drawn so as not to be invalid, prohibited or
unenforceable in such jurisdiction, it shall, as to such jurisdiction, be so narrowly drawn, without invalidating the remaining provisions of this Release Agreement or affecting the validity or enforceability of such provision in any other
jurisdiction. 
 10. Counterparts. This Release Agreement may be executed in separate counterparts, each of which is
deemed to be an original and all of which taken together constitute one and the same agreement. Signatures delivered by facsimile shall be deemed effective for all purposes. 
 11. Governing Law. THIS RELEASE AGREEMENT WILL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH UNITED STATES FEDERAL LAW AND, TO THE EXTENT NOT PREEMPTED BY UNITED STATES FEDERAL LAW, THE LAWS OF
THE STATE OF MARYLAND, WITHOUT GIVING EFFECT TO ANY CHOICE OF LAW OR CONFLICTING PROVISION OR RULE (WHETHER OF THE STATE OF MARYLAND OR ANY OTHER JURISDICTION) THAT WOULD CAUSE THE LAWS OF ANY JURISDICTION OTHER THAN UNITED STATES FEDERAL LAW AND
THE LAW OF THE STATE OF MARYLAND TO BE APPLIED. IN FURTHERANCE OF THE FOREGOING, APPLICABLE FEDERAL LAW AND, TO THE EXTENT NOT PREEMPTED BY APPLICABLE FEDERAL LAW, THE INTERNAL LAW OF THE STATE OF MARYLAND, WILL CONTROL THE INTERPRETATION AND
CONSTRUCTION OF THIS RELEASE AGREEMENT, EVEN IF UNDER SUCH JURISDICTION’S CHOICE OF LAW OR CONFLICT OF LAW ANALYSIS, THE SUBSTANTIVE LAW OF SOME OTHER JURISDICTION WOULD ORDINARILY APPLY. 

12. Amendment and Waiver. The provisions of this Release Agreement may be amended and waived only with the prior written consent
of a duly authorized officer of the Company and Executive, and no course of conduct or failure or delay in enforcing the provisions of this Release Agreement shall be construed as a waiver of such provisions or affect the validity, binding effect or
enforceability of this Release Agreement or any provision hereof. 
 13. Integration. The Company and Executive
acknowledge and agree that this Release Agreement, including the Addendum and the Bring Down Release, constitutes the entire agreement between the parties; that the parties have executed this Release Agreement based upon the terms set forth herein;
that the parties have not relied on any prior agreement or representation, whether oral or written, which is not set forth in this Release Agreement; that no prior agreement, whether oral or written, shall have any effect on the terms and provisions
of this Release Agreement; and that all prior agreements, whether oral or written, are expressly superseded and/or revoked by this Release Agreement. 

  
 5 

 14. Construction. Where specific language is used to clarify by example a general
statement contained herein, such specific language shall not be deemed to modify, limit or restrict in any manner the construction of the general statement to which it relates. The language used in this Release Agreement shall be deemed to be the
language chosen by the parties to express their mutual intent, and no rule of strict construction shall be applied against any party. 
 15. No Wrongdoing. This Release Agreement does not constitute an adjudication or finding on the merits and is not, and shall not be construed as, an admission or acknowledgment by any party of any
violation of any policy, procedure, state or federal law or regulation, or any unlawful or improper act or conduct, all of which is expressly denied. Moreover, neither this Release Agreement nor anything in this Release Agreement shall be construed
to be, or shall be, admissible in any proceeding as evidence of or an admission by any party of any violation of any policy, procedure, state or federal law or regulation, or any unlawful or improper act or conduct. This Release Agreement may be
introduced, however, in any proceeding to enforce this Release Agreement. 
 16. Legal Counsel. The parties hereto
recognize that this Release Agreement is a legally binding contract and acknowledge and agree that they have had the opportunity to consult with legal counsel of their choice. Executive acknowledges and agrees that he has read and understands this
Release Agreement completely, is entering into it freely and voluntarily, and had been advised to seek counsel prior to entering into this Release Agreement and he has had ample opportunity to do so. 

17. Cooperation with Litigation. In the event that the Company or any of its affiliates is involved in any investigation,
litigation, arbitration or administrative proceeding subsequent to the Resignation Date, Executive agrees that, upon reasonable request, Executive will provide reasonable cooperation to the Company. Reasonable fees and business travel expenses for
such purposes will be paid by the Company. 
 18. Nouns and Pronouns. Whenever the context may require, any pronouns used
herein shall include the corresponding masculine, feminine or neuter forms, and the singular form of nouns and pronouns shall include the plural and vice-versa. 
 19. Section 409A. For purposes of Section 409A of the Internal Revenue Code (including, without limitation, for purposes of Treasury Regulation Section 1.409A-2(b)(2)(iii)), each
payment that the Executive may be eligible to receive under this Release Agreement shall be treated as a separate and distinct payment. To the extent applicable, this Agreement shall be interpreted in accordance with Section 409A of the
Internal Revenue Code and Department of Treasury regulations and other interpretative guidance issued thereunder, including without limitation any such regulations or other such guidance that may be issued after the date hereof. 

[Remainder of page intentionally left blank] 

  
 6 

 Exhibit 10.26 
 The undersigned have read and understand the consequences of this Release Agreement and voluntarily sign it. 

 

			
	EXECUTIVE
		
	By:	 	 /s/ Bruce F. Metge

		 	Bruce Metge
	
	CATALYST HEALTH SOLUTIONS, INC.
		
	By:	 	 /s/ David T. Blair

	Name:	 	David T. Blair
	Title:	 	Chairman & Chief Executive Officer

  
 7 

 Exhibit A 

BRING DOWN RELEASE 

Reference is made to that certain Separation and Release Agreement, dated as of February     , 2012 (the
“Agreement”). Capitalized terms not defined herein shall have the meaning set forth in the Agreement. 
 For
and in consideration of the benefits due to Executive pursuant to Section 2 of the Agreement, Executive hereby re-affirms the release of claims set forth in Sections 5 and 6 of the Agreement, subject to the terms, conditions, limitations and
exclusions therein, as if such release of claims were executed on the date hereof. 
 Nothing herein shall release or affect
Executive’s right to receive the payments and benefits set forth in the Agreement. Section 11 of the Agreement shall also apply to this Bring Down Release. 
 Executive has been given twenty-one (21) days to review and consider this Bring Down Release and has been advised to discuss this Bring Down Release with an attorney. Executive has read this Bring
Down Release and understands its terms. By signing below, Executive acknowledges that he has had the opportunity to consult an attorney with regard to the execution of this Bring Down Release and, if he signs this Bring Down Release prior to the
expiration of such 21-day period, having had the opportunity for advice of counsel, expressly waives the 21-day period for consideration of the Bring Down Release. By signing below, Executive acknowledges he has been provided with ample and
sufficient time to fully consider the Bring Down Release and its terms. 
 Executive has seven (7) days following the
signing of this Bring Down Release to revoke it, in which case the Agreement shall not be effective and Executive will not receive the benefits set out in Section 2 of the Agreement. Executive understands that he will not receive any payments
under Section 2 of the Agreement until the revocation period has passed. Notice of revocation must be submitted in writing by Executive to Benjamin Preston, General Counsel, Catalyst Health Solutions, Inc., 800 King Farm Boulevard, Rockville,
Maryland 20850 no later than the expiration of such revocation period. 
 Executed this     day of
                    , 2012. 
  

	
	  

 Bruce Metge 

  
 8

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00199-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00199-of-00352.parquet"}]]